Second Malignant Neoplasms in Testicular Cancer Survivors

View More View Less
  • a From the Department of Medical Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York; Norwegian Radium Hospital, Oslo, Norway; Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; and Rubin Center for Cancer Survivorship and Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York.
Restricted access

Second malignant neoplasms (SMNs) are a potentially life-threatening late effect of testicular cancer (TC) and its therapy. Although the increased risk for developing solid tumors among TC survivors is largely attributed to radiotherapy, chemotherapy may also be associated with excess risks. However, the baseline risks of developing site-specific SMNs in TC survivors have not yet been quantified, nor have interactions between treatments and other risk factors been elucidated. Studies to date report overall relative risks ranging from 1.4- to 2.8-fold for SMN in TC survivors, with significantly elevated risks apparent for more than 35 years. Analytic investigations show relationships between increasing radiation dose and/or field size and solid tumor risk. Small excess risks of leukemia follow treatment with either chemotherapy or radiotherapy. Recently, concern has been expressed about the increased risk of SMN from radiation exposure during imaging surveillance for recurrence. A small number of studies have examined this issue, generating inconclusive results. Given the current changes in TC treatment that result in lower radiation doses, in the future solid tumors will likely have a considerably lower impact on the lives of TC survivors, although diligent follow-up will be required to accurately quantify long-term risks and to ascertain risks associated with chemotherapy.

Correspondence: Lois B. Travis, MD, ScD, Rubin Center for Cancer Survivorship and Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, 265 Crittenden Boulevard, Box CU420318, Rochester, NY 14642. E-mail: lois_travis@urmc.rochester.edu
  • 1

    Howlader N, Noone AM, Krapcho M., eds. SEER Cancer Statistics Review, 1975–2008. Surveillance Epidemiology and End Results Web site. Available at: http://seer.cancer.gov/csr/1975_2008/. Accessed October 12, 2011.

    • Search Google Scholar
    • Export Citation
  • 2

    Travis LB, Beard C, Allan JM. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:11141130.

    • Search Google Scholar
    • Export Citation
  • 3

    Richiardi L, Scelo G, Boffetta P. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007;120:623631.

    • Search Google Scholar
    • Export Citation
  • 4

    Li C, Ekwueme DU, Rim SH, Tangka FK. Years of potential life lost and productivity losses from male urogenital cancer deaths—United States, 2004. Urology 2010;76:528535.

    • Search Google Scholar
    • Export Citation
  • 5

    Bachaud JM, Berthier F, Soulie M. Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma. Radiother Oncol 1999;50:191197.

    • Search Google Scholar
    • Export Citation
  • 6

    Fossa SD, Langmark F, Aass N. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer 1990;61:639643.

    • Search Google Scholar
    • Export Citation
  • 7

    Hemminki K, Liu H, Sundquist J. Second cancers after testicular cancer diagnosed after 1980 in Sweden. Ann Oncol 2010;21:15461551.

  • 8

    Travis LB, Andersson M, Gospodarowicz M. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:11651171.

  • 9

    Travis LB, Curtis RE, Storm H. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:14291439.

    • Search Google Scholar
    • Export Citation
  • 10

    Travis LB, Fossa SD, Schonfeld SJ. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:13541365.

    • Search Google Scholar
    • Export Citation
  • 11

    van den Belt-Dusebout AW, de Wit R, Gietema JA. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:43704378.

    • Search Google Scholar
    • Export Citation
  • 12

    van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11:415424.

    • Search Google Scholar
    • Export Citation
  • 13

    Wanderas EH, Fossa SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 1997;33:253262.

    • Search Google Scholar
    • Export Citation
  • 14

    Jones WG, Fossa SD, Mead GM. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:12001208.

    • Search Google Scholar
    • Export Citation
  • 15

    Oliver RT, Mead GM, Rustin GJ. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011;29:957962.

    • Search Google Scholar
    • Export Citation
  • 16

    Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007;64:182197.

    • Search Google Scholar
    • Export Citation
  • 17

    Albers P, Albrecht W, Algaba F. EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011;60:304319.

  • 18

    Classen J, Schmidberger H, Meisner C. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:11011106.

    • Search Google Scholar
    • Export Citation
  • 19

    Patterson H, Norman AR, Mitra SS. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 2001;59:511.

    • Search Google Scholar
    • Export Citation
  • 20

    Schmidberger H, Bamberg M, Meisner C. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys 1997;39:321326.

    • Search Google Scholar
    • Export Citation
  • 21

    Garcia-del-Muro X, Maroto P, Guma J. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group study. J Clin Oncol 2008;26:54165421.

    • Search Google Scholar
    • Export Citation
  • 22

    Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293298.

    • Search Google Scholar
    • Export Citation
  • 23

    Donohue JP, Thornhill JA, Foster RS. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995;153:8589.

    • Search Google Scholar
    • Export Citation
  • 24

    Foster R, Bihrle R. Current status of retroperitoneal lymph node dissection and testicular cancer: when to operate. Cancer Control 2002;9:277283.

    • Search Google Scholar
    • Export Citation
  • 25

    Stephenson AJ, Bosl GJ, Motzer RJ. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005;23:27812788.

    • Search Google Scholar
    • Export Citation
  • 26

    Oechsle K, Bokemeyer C. Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin North Am 2011;25:605613, ix.

  • 27

    Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 2003;111:7683; discussion 83–85.

  • 28

    Read G, Stenning SP, Cullen MH. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:17621768.

    • Search Google Scholar
    • Export Citation
  • 29

    Warde P, Huddart R, Bolton D. Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology 2011;78(4 Suppl):S435443.

    • Search Google Scholar
    • Export Citation
  • 30

    Chamie K, Kurzrock EA, Evans CP. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer 2011;117:42194230.

  • 31

    Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009;181:627632; discussion 632–633.

    • Search Google Scholar
    • Export Citation
  • 32

    van Walraven C, Fergusson D, Earle C. Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol 2011;29:28832888.

    • Search Google Scholar
    • Export Citation
  • 33

    International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594603.

    • Search Google Scholar
    • Export Citation
  • 34

    Bajorin DF, Sarosdy MF, Pfister DG. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;11:598606.

    • Search Google Scholar
    • Export Citation
  • 35

    Kondagunta GV, Bacik J, Bajorin D. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005;23:92909294.

    • Search Google Scholar
    • Export Citation
  • 36

    Kondagunta GV, Bacik J, Donadio A. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005;23:65496555.

    • Search Google Scholar
    • Export Citation
  • 37

    Loehrer PJ Sr, Gonin R, Nichols CR. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998;16:25002504.

    • Search Google Scholar
    • Export Citation
  • 38

    Nichols CR, Catalano PJ, Crawford ED. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 1998;16:12871293.

    • Search Google Scholar
    • Export Citation
  • 39

    Williams SD, Birch R, Einhorn LH. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:14351440.

    • Search Google Scholar
    • Export Citation
  • 40

    Travis LB, Bhatia S, Allan JM. Second primary cancers. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:23932410.

    • Search Google Scholar
    • Export Citation
  • 41

    van den Belt-Dusebout AW, Aleman BM, Besseling G. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009;75:14201429.

    • Search Google Scholar
    • Export Citation
  • 42

    Zwahlen DR, Martin JM, Millar JL, Schneider U. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2008;70:853858.

    • Search Google Scholar
    • Export Citation
  • 43

    Fossa SD, Horwich A, Russell JM. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999;17:1146.

    • Search Google Scholar
    • Export Citation
  • 44

    Kollmannsberger C, Beyer J, Droz JP. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998;16:33863391.

    • Search Google Scholar
    • Export Citation
  • 45

    Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 1999;83:860863.

    • Search Google Scholar
    • Export Citation
  • 46

    Travis LB, Holowaty EJ, Bergfeldt K. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351357.

  • 47

    Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993;11:17031709.

  • 48

    Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999;83:866869.

    • Search Google Scholar
    • Export Citation
  • 49

    Stewart DJ, Mikhael NZ, Nanji AA. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. J Clin Oncol 1985;3:12511256.

    • Search Google Scholar
    • Export Citation
  • 50

    Tothill P, Klys HS, Matheson LM. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 1992;28A:13581361.

    • Search Google Scholar
    • Export Citation
  • 51

    Uozumi J, Ueda T, Yasumasu T. Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans. Int Urol Nephrol 1993;25:215220.

    • Search Google Scholar
    • Export Citation
  • 52

    Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005;5:943955.

  • 53

    Claij N, te Riele H. Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res 1999;246:110.

  • 54

    Robinson E, Neugut AI. Clinical aspects of multiple primary neoplasms. Cancer Detect Prev 1989;13:287292.

  • 55

    Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005;44:1322.

  • 56

    Nieder C, Milas L, Ang KK. Tissue tolerance to reirradiation. Semin Radiat Oncol 2000;10:200209.

  • 57

    Tibbs MK. Wound healing following radiation therapy: a review. Radiother Oncol 1997;42:99106.

  • 58

    Schairer C, Hisada M, Chen BE. Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst 2007;99:12481256.

    • Search Google Scholar
    • Export Citation
  • 59

    Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med 2007;357:22772284.

  • 60

    Smith-Bindman R, Lipson J, Marcus R. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009;169:20782086.

    • Search Google Scholar
    • Export Citation
  • 61

    Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: The National Academies Press; 2005.

  • 62

    O’Malley ME, Chung P, Haider M. Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. Eur Radiol 2010;20:16241630.

    • Search Google Scholar
    • Export Citation
  • 63

    Fung C, Vaughn DJ. Complications associated with chemotherapy in testicular cancer management. Nat Rev Urol 2011;8:213222.

  • 64

    Feldman DR. The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization. Oncology (Williston Park) 2010;24:761763.

    • Search Google Scholar
    • Export Citation
  • 65

    Buchler T, Kubankova P, Boublikova L. Detection of second malignancies during long-term follow-up of testicular cancer survivors. Cancer 2011;117:42124218.

    • Search Google Scholar
    • Export Citation
  • 66

    Travis LB, Ng AK, Allan JM. Second malignant neoplasms and cardiovascular disease after radiotherapy. J Natl Cancer Inst 2012;104:357370.

  • 67

    Best T, Li D, Skol AD. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin’s lymphoma. Nat Med 2011;17:941943.

    • Search Google Scholar
    • Export Citation
  • 68

    Knight JA, Skol AD, Shinde A. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009;113:55755582.

    • Search Google Scholar
    • Export Citation
  • 69

    Travis LB, Rabkin CS, Brown LM. Cancer survivorship— genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006;98:1525.

    • Search Google Scholar
    • Export Citation
  • 70

    Berrington de Gonzalez A, Mahesh M, Kim KP. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009;169:20712077.

    • Search Google Scholar
    • Export Citation
  • 71

    Kushi LH, Doyle C, McCullough M. American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012;32:3067.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 127 70 5
PDF Downloads 53 37 7
EPUB Downloads 0 0 0